clinical trial · NCT06442436
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
Merck Sharp & Dohme LLC·phase1·recruiting·n = 32
Hepatic Impairment (HI)Nemtabrutinib
brief summary
The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemtabrutinib (MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic impairment to that of healthy matched control participants and to evaluate the safety and tolerability of nemtabrutinib.
started
Jul 24, 2024
primary completion
Sep 14, 2026
completion
Sep 14, 2026
last updated
Jul 10, 2026
official title
A Study to Evaluate the Pharmacokinetics of Nemtabrutinib in Participants With Moderate Hepatic Impairment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol